Patheon Broadens Its Pharma Client Base With Mova Acquisition
This article was originally published in The Pink Sheet Daily
Mova’s “excellent relationships with some of the largest pharmaceutical companies in the world,” including Merck, are a major attraction for Patheon, CEO Tedford says. The acquisition, valued at $350 mil., is expected to close in late December.
You may also be interested in...
Despite an effect on supply, Abbott said Omnicef oral suspension will remain available for patients who rely on the antibiotic.
Italy claims to have pushed farther into managed entry agreements than other European countries with strong clawback provisions on new drugs – particularly cancer drugs – if they don't work as well as their manufacturers claim. The financial clawbacks are supported by extensive outcome data collection across the country's twenty regions.